Home » Stocks » LIFE

aTyr Pharma, Inc. (LIFE)

Stock Price: $4.27 USD -0.05 (-1.16%)
Updated Mar 4, 2021 1:24 PM EST - Market open
Market Cap 44.00M
Revenue (ttm) 8.55M
Net Income (ttm) -17.27M
Shares Out 9.65M
EPS (ttm) -2.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 4
Last Price $4.27
Previous Close $4.32
Change ($) -0.05
Change (%) -1.16%
Day's Open 4.26
Day's Range 4.22 - 4.48
Day's Volume 351,900
52-Week Range 2.13 - 8.33

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 2 weeks ago

These seven names have shown important insider trading signals after their rallies, meaning some insiders are taking profits in these stocks. The post 7 Stocks With Important Insider Trading S...

Other stocks mentioned: ANGI, PLAN, SMAR, SVMK, TW, TWTR
Benzinga - 3 weeks ago

aTyr Pharma Inc (NASDAQ: LIFE) has initiated two discovery programs from its tRNA synthetase platform that will investigate the functionality of selected fragments of Alanyl-tRNA Synthetase (A...

GlobeNewsWire - 3 weeks ago

Advancement of selected AARS and DARS fragments primarily targeting cancer

GlobeNewsWire - 3 weeks ago

SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biologi...

GlobeNewsWire - 1 month ago

Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition.

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biologi...

GlobeNewsWire - 1 month ago

Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients.

Seeking Alpha - 3 months ago

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

C omplete s e nrollment of ATYR1923 c linical t rial in patients with COVID-19 s evere r espiratory c omplications . Topline data is expected at turn of calendar year.

GlobeNewsWire - 3 months ago

Peer-reviewed paper supports aTyr's antibody program .

Zacks Investment Research - 3 months ago

Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biologi...

InvestorPlace - 5 months ago

Although penny stocks come with an added element of risk, investing in the right stocks could set you up for massive gains in the future. Here are the best penny stocks to buy right now.

Other stocks mentioned: EROS, RFIL
GlobeNewsWire - 5 months ago

Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in Japanese healthy volunteers Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 i...

GlobeNewsWire - 5 months ago

Aspire Capital commits to purchase up to $20 Million of Common Stock over a period of up to 30 months.

InvestorPlace - 5 months ago

These penny stocks are company names that won’t break the bank, and boast colossal growth prospects for the 12 months ahead. The post 3 Penny Stocks That Have Triple-Digit Upside Potential ap...

Other stocks mentioned: AMRS, BXRX
GlobeNewsWire - 5 months ago

SAN DIEGO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immu...

GlobeNewsWire - 6 months ago

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (the “Company”) (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines bas...

Seeking Alpha - 6 months ago

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 5.48% and -52.75%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

Company to host conference call and webcast today, August 13, at 5:00 p.m. EDT / 2:00 p.m. PDT Company to host conference call and webcast today, August 13, at 5:00 p.m. EDT / 2:00 p.m. PDT 

GlobeNewsWire - 6 months ago

Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in healthy volunteers in Japan. Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 ...

GlobeNewsWire - 6 months ago

Management to host conference call and webcast on August 13th at 5:00 pm EDT / 2:00 pm PDT Management to host conference call and webcast on August 13th at 5:00 pm EDT / 2:00 pm PDT

Zacks Investment Research - 6 months ago

Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 8 months ago

Poster details data from aTyr’s preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies may increase sensitivity to chemotherapy in triple-negative breast cancer.

GlobeNewsWire - 8 months ago

 Discovery that Neuropilin b1 domain acts as a binding site for SARS-CoV-2 Spike protein and aids viral entry.  Lead therapeutic candidate, ATYR1923, modulates Neuropilin pathway to dampen in...

GlobeNewsWire - 8 months ago

Trial opens for enrollment of hospitalized patients at multiple centers throughout the U.S. Trial opens for enrollment of hospitalized patients at multiple centers throughout the U.S.

Zacks Investment Research - 8 months ago

Atyr Pharma (LIFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GuruFocus - 9 months ago

Andreas Halvorsen (Trades, Portfolio)’s Viking Global Investors bought shares of the following stocks in both the fourth quarter of 2019 and the first quarter of 2020.

Other stocks mentioned: AIZ, AVTR, BPMC, BSX, CI, FTV, V
Seeking Alpha - 9 months ago

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 238.89% and 83.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 9 months ago

Company to host conference call and webcast today, May 12, at 5:00 p.m. EDT / 2:00 p.m. PDT Company to host conference call and webcast today, May 12, at 5:00 p.m. EDT / 2:00 p.m. PDT

GlobeNewsWire - 9 months ago

Abstracts originally accepted for presentation at the 2020 American Thoracic Society (ATS) International Conference

GlobeNewsWire - 10 months ago

SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immu...

Zacks Investment Research - 11 months ago

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 3.14% and 69.41%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 11 months ago

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 3.14% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 11 months ago

Grant awarded by the Hong Kong Government's Innovation and Technology Commission under the Partnership Research Program

GlobeNewsWire - 11 months ago

SAN DIEGO, March 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immu...

GlobeNewsWire - 1 year ago

Paper highlights the essential role that histidyl tRNA synthetase (HARS) plays in immune responses in a broad range of inflammatory disease states

Zacks Investment Research - 1 year ago

aTyr Pharma (LIFE) soars on a collaboration and license agreement with Kyorin Pharmaceutical for lead candidate.

Benzinga - 1 year ago

Shares of the thinly traded nano-cap biotech aTyr Pharma Inc (NASDAQ: LIFE) were advancing strongly Monday on above-average volume.

GlobeNewsWire - 1 year ago

aTyr eligible to receive up to $175 million in total payments, including $8 million upfront, plus tiered sales royalties

GlobeNewsWire - 1 year ago

ATYR1923 safe and well tolerated in initial 15 randomized patients with pulmonary sarcoidosis

Seeking Alpha - 1 year ago

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

aTyr Pharma's (LIFE) CEO Sanjay Shukla on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Atyr Pharma (LIFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 1 year ago

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q4 2018 Results - Earnings Call Transcript

About LIFE

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the d... [Read more...]

Industry
Biotechnology
IPO Date
May 7, 2015
CEO
Sanjay Shukla
Employees
39
Stock Exchange
NASDAQ
Ticker Symbol
LIFE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for aTyr Pharma stock is "Buy." The 12-month stock price forecast is 13.33, which is an increase of 212.18% from the latest price.

Price Target
$13.33
(212.18% upside)
Analyst Consensus: Buy